Gabitril Generalized Anxiety Disorder Filing Anticipated Mid-Year
This article was originally published in The Pink Sheet Daily
Executive Summary
Cephalon expects the results of Phase III studies supporting the anti-seizure medication for generalized anxiety will be available in Q2.